In fact, we found that inhibiting Th2 differentiation using monoclonal antibodies directed against interleukin-4 (IL-4) or interleukin-13 (IL-13) markedly decreased fibrosis, leading to resolution of pathologies associated with lymphedema and restoration of lymphatic function [16]. The gene discussed is IL13; the disease is lymphedema.